American Journal of Cardiovascular Drugs

, Volume 5, Issue 1, pp 17–22

Fixed-Dose Combinations in the Management of Hypertension

Defining the Place of Angiotensin Receptor Antagonists and Hydrochlorothiazide
  • Sverre E. Kjeldsen
  • Ingrid Os
  • Aud Høieggea
  • Kim Beckey
  • Gilbert W. Gleim
  • Suzanne Oparil
Review Article

Abstract

We discuss combination therapy with angiotensin receptor antagonists (angiotensin receptor blockers; ARBs) and thiazide diuretics in light of the independent actions of both types of agents, and the adverse effects of both agents independently and in the context of the physiologic synergy achieved in using these agents together. ARBs counteract many of the adverse events associated with the use of thiazide diuretics and have been shown to reduce the occurrence of new-onset diabetes mellitus. We also review outcome trials in patients with hypertension (such as LIFE [Losartan Intervention For Endpoint reduction in hypertension], VALUE [Valsartan Antihypertensive Long-term Use Evaluation], and SCOPE [Study on COgnition and Prognosis in the Elderly]), in which losartan, valsartan, and candesartan cilexetil were used in combination with hydrochlorothiazide. Fixed combination ARB/hydrochlorothiazide agents make sense as initial therapy for patients in whom BP is >20/ 10mm Hg above goal.

References

  1. 1.
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report JAMA 2003; 289: 2560–71PubMedCrossRefGoogle Scholar
  2. 2.
    Amer J. Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study). J Hypertens 2002; 20: 779–84CrossRefGoogle Scholar
  3. 3.
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2002; 288: 2981-97Google Scholar
  4. 4.
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003PubMedCrossRefGoogle Scholar
  5. 5.
    European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension: Guidelines Committee 2003. J Hypertens 2003; 6: 1011–53Google Scholar
  6. 6.
    Mudge GH. Diuretics and other agents employed in the mobilization of edema fluid. In: Gilman AG, Goodman LS, Oilman A, editors. The pharmacological basis of therapeutics. New York: Macmillan Publishing Co, 1980: 892–915Google Scholar
  7. 7.
    Carter BL, Emst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4–9PubMedCrossRefGoogle Scholar
  8. 8.
    Goth A. Diuretic drugs. In: Goth A, editor. Medical pharmacology. St Louis: CV Mosby, 1978: 426–44Google Scholar
  9. 9.
    Weiner IM, Mudge GH. Diuretics and other agents employed in the mobilization of edema fluid. In: Gilman AG, Goodman LS, Rall TW, et al, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: Macmillan Publishing Co, 1985: 895Google Scholar
  10. 10.
    Roberts CJ, Marshall AJ, Heaton S, et al. Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and Spironolactone. BMJ 1979; 1: 224–6PubMedCrossRefGoogle Scholar
  11. 11.
    Gibbs CR, Beevers DG. Angiotensin receptor antagonism with losartan and the regression of left ventricular hypertrophy. J Hum Hypertens 1998; 12: 493–5PubMedCrossRefGoogle Scholar
  12. 12.
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9PubMedCrossRefGoogle Scholar
  13. 13.
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60PubMedCrossRefGoogle Scholar
  14. 14.
    Hasser EM, Cunningham JT, Sullivan MJ, et al. Area postrema and sympathetic nervous system effects of Vasopressin and angiotensin II. Clin Exp Pharmacol Physiol 2000; 27: 432–6PubMedCrossRefGoogle Scholar
  15. 15.
    Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-{gamma} activity. Circulation 2004; 109: 2054–7PubMedCrossRefGoogle Scholar
  16. 16.
    Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with Captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study: ELITE II. Lancet 2000; 355: 1582–7PubMedCrossRefGoogle Scholar
  17. 17.
    Dickstein K, Kjekshus J. Effects of losartan and Captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752–60PubMedCrossRefGoogle Scholar
  18. 18.
    Conn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure: the Valsartan Heart Failure Trial Investigators. N Engl J Med 2001; 345: 1667–75CrossRefGoogle Scholar
  19. 19.
    Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906PubMedCrossRefGoogle Scholar
  20. 20.
    Julius PS, Kjeldsen PS, Weber PM, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31PubMedCrossRefGoogle Scholar
  21. 21.
    Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86PubMedCrossRefGoogle Scholar
  22. 22.
    Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66PubMedCrossRefGoogle Scholar
  23. 23.
    Hall J, Marbury T, Gray J, et al. Long term safety, tolerability and efficacy of valsartan: results from one and two year trials. J Clin Res 1998; 1: 147–59Google Scholar
  24. 24.
    Goldberg AI, Dunlay MC, Sweet CS. Safety of losartan. Am J Cardiol 1995; 75: 793–5PubMedCrossRefGoogle Scholar
  25. 25.
    Laragh J. Laragh’s lessons in renin system pathophysiology for treating hypertension and its fatal cardiovascular consequences. New York: Elsevier, 2002Google Scholar
  26. 26.
    Lindhohn LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563–74CrossRefGoogle Scholar
  27. 27.
    Elliott WJ, Calhoun DA, DeLucca PT, et al. Losartan versus vaisartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 2001; 23: 1166–79PubMedCrossRefGoogle Scholar
  28. 28.
    Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–9PubMedCrossRefGoogle Scholar
  29. 29.
    Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418–26PubMedCrossRefGoogle Scholar
  30. 30.
    Chrysant SG, Weber MA, Wang A, et al. Factorial design to assess the safety and efficacy of olmesartan medoxomil and hydrochlorothiazide combination therapy. Am J Hypertens 2003; 16: 110A–1ACrossRefGoogle Scholar
  31. 31.
    McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833–50PubMedCrossRefGoogle Scholar
  32. 32.
    Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with hydrochlorothiazide in patients with essential hypertension. J Hum Hypertens 2002; 16: 169–76PubMedCrossRefGoogle Scholar
  33. 33.
    Dahlof B, Devereux RB, Kjeldsen SE. Diuretics in the LIFE study [letter]. Lancet 2004. 364: 413–4CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Sverre E. Kjeldsen
    • 1
    • 2
  • Ingrid Os
    • 3
    • 4
  • Aud Høieggea
    • 4
  • Kim Beckey
    • 5
  • Gilbert W. Gleim
    • 5
  • Suzanne Oparil
    • 6
  1. 1.Department of CardiologyUllevaal University HospitalOsloNorway
  2. 2.Division of Cardiovascular MedicineUniversity of MichiganAnn ArborUSA
  3. 3.Institute of PharmacotherapyUniversity of Oslo Medical SchoolOsloNorway
  4. 4.Department of NephrologyUllevaal University HospitalOsloNorway
  5. 5.Merck Research LabsWest PointUSA
  6. 6.University of Alabama Vascular Biology and Hypertension ProgramBirminghamUSA

Personalised recommendations